Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366413 · ClinicalTrials.gov registry record · NA
Early Interventional Treatment for Cancer Pain
A NA study of Cancer Pain, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05366413: Completed NA study of Cancer Pain, sponsored by Dana-Farber Cancer Institute.
NCT05366413 is a NA study of Cancer Pain that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 160-participant average among 15 other Cancer Pain trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05366413, a NA study of Cancer Pain, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to evaluate how feasible and beneficial it is to refer patients with cancer pain to a doctor who specializes in pain management, including procedures to relieve pain, and whether this is helpful to patients with pain related to their cancer.
Primary Outcome
Feasibility will be measured by the percentage of patients that have an interventional pain consultation within 4 weeks, with a threshold for determining feasibility of at least 80% of participants.
Conditions Studied
Interventions
- OTHER Early Referral
- OTHER Pain Management Strategies
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2024-10-26 |
| Phase | NA |
What the finished NCT05366413 record still lists
NCT05366413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 160-participant average among 15 other Cancer Pain trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Cancer Pain appearing as the primary indexed condition, and to 2 interventions - of which Early Referral is the first listed.
NCT05366413 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05366413 about?
NCT05366413 is a clinical study titled "Early Interventional Treatment for Cancer Pain". The purpose of the study is to evaluate how feasible and beneficial it is to refer patients with cancer pain to a doctor who specializes in pain management, including procedures to relieve pain, and whether this is helpful to patients with pain related to their cancer.
What is the current status of trial NCT05366413?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-06-02. Estimated completion is 2024-10-26.
What conditions does trial NCT05366413 study?
This clinical trial studies the following conditions: Cancer Pain.
What interventions are being tested in trial NCT05366413?
The interventions under investigation include: Early Referral (OTHER), Pain Management Strategies (OTHER).
Who is sponsoring clinical trial NCT05366413?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05366413 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05366413's enrollment target sits among peer trials
30 12th of 15 higher than 2 of 15 other Cancer Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN)
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
RECRUITING · NA
-
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
RECRUITING · NA
-
Cancer Pain Management Using a Web-based Intervention
RECRUITING · NA
-
Virtual Reality Therapy for Cancer-Treatment Associated Symptoms
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI